Cutting-edge Biology and Chemistry
Life-changing Technologies for Smarter Medicines
Target validation remains a bottleneck for the development of innovative medicines, primarily due to the complexity of the biology and pathology of a given disease. The true link between a disease and a molecular target is still largely established in late stage clinical trials.
Developed by GP Smith (2018 Nobel Laureate in Chemistry), phage display technique has been widely used in peptide, protein, as well as antibody engineering. Encapsulating the ssDNA gene, phage particles display the protein encoded by the gene on the surface, providing a physical linkage between phenotype and genotype.
The hybridoma technology is a traditional but still widely used method to produce monoclonal antibodies. The B lymphocytes secrete monoclonal antibodies but cannot replicate themselves in culture. On the other hand, the myeloma cells do not produce antibody but can replicate in culture easily.
Sparx Multi-Component Nanotechnology Platform – SPARX MULCOMTM – is an advanced drug delivery polymer-lipid hybrid technology designed to deliver multiple drugs and biologics for combination therapy. With our SPARX MULCOMTM, stable nanoparticles encapsulating molecules with multiple properties within the same particle via self-assembly processes are formed.
LEMMAbTM (Linker Enhanced Mono-chained Multi-specific Antibody) is our proprietary technology platform that uses natural IgG with Fc in constructing bispecific or multi-specific antibody for cutting-edge biomedical research and development. Owing to the single chain and symmetrical nature, LEMMAbTM antibodies resulting from this technology are free of mismatches, more soluble, less prone to aggregate, simpler to purify, and expressed in higher yield. These types of antibodies tend to have decreased immunogenicity and improved binding affinity, safety profiles, and developability.
SMARTOPTM (Symmetric Multispecific Antibodies with Relative-affinities fine-Tuned by phage Off-rate and PH-selections) is another proprietary technology platform that constructs novel bispecific or multi-specific antibodies for biotech and pharmaceutical research and development. SMARTOP™ antibodies shares several features with LEMMAb™ antibodies as this type of antibodies are also symmetrical and free of mismatches, more soluble, less prone to aggregate, simpler to purify, and expressed in higher yield. In addition, SMARTOPTM antibodies are selected by slower off-rate and better tolerance for the lower pH values in tumor microenvironment. As a result, SMARTOP™ antibodies tend to have improved tumor retention and more tailored target engaging kinetics. They also enjoy decreased immunogenicity and improved binding affinity, safety profiles, and developability.
Equipped with critical technologies for pharmaceutical innovations, such as the Big Data-Aided Target Mining Technology, Antibody Phage Display and Hybridoma Antibody Discovery technologies, as well as the Sparx Multi-Component Nanotechnology Platform – SPARX MULCOMTM, Sparx has generated a rich development pipeline for the treatment of cancer and CNS diseases.